Friday, Nov. 6, 2015, 72 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $473.82 to $10,527,076.00.

Highlighted Stocks Traded by Insiders:

Bryn Mawr Bank (BMTC) - FREE Research Report

Harrington Michael W, who is CFO & Treasurer at Bryn Mawr Bank, bought 1,000 shares at $29.96 on Nov. 6, 2015. Following this transaction, the CFO & Treasurer owned 7,000 shares meaning that the stake was boosted by 16.67% with the 1,000-share transaction.

The shares most recently traded at $30.20, up $0.24, or 0.79% since the insider transaction. Historical insider transactions for Bryn Mawr Bank go as follows:

  • 4-Week # shares sold: 1,250
  • 12-Week # shares sold: 1,250
  • 24-Week # shares sold: 1,250

The average volume for Bryn Mawr Bank has been 70,500 shares per day over the past 30 days. Bryn Mawr Bank has a market cap of $532.5 million and is part of the financial sector and banking industry. Shares are down 3.19% year-to-date as of the close of trading on Friday.

Bryn Mawr Bank Corporation operates as the bank holding company for The Bryn Mawr Trust Company that provides commercial and retail banking business to individuals and businesses. The stock currently has a dividend yield of 2.67%. The company has a P/E ratio of 16.6. Currently, there is 1 analyst who rates Bryn Mawr Bank a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on BMTC - FREE

TheStreet Quant Ratings

rates Bryn Mawr Bank as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, increase in net income, reasonable valuation levels and expanding profit margins. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full

Bryn Mawr Bank Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Hawaiian Holdings (HA) - FREE Research Report

Dunkerley Mark B, who is President and CEO at Hawaiian Holdings, sold 13,000 shares at $37.00 on Nov. 6, 2015. Following this transaction, the President and CEO owned 924,068 shares meaning that the stake was reduced by 1.39% with the 13,000-share transaction.

The shares most recently traded at $35.96, down $1.04, or 2.89% since the insider transaction. Historical insider transactions for Hawaiian Holdings go as follows:

  • 4-Week # shares sold: 142,495
  • 12-Week # shares sold: 194,822
  • 24-Week # shares bought: 9,209
  • 24-Week # shares sold: 223,322

The average volume for Hawaiian Holdings has been 1.2 million shares per day over the past 30 days. Hawaiian Holdings has a market cap of $2.0 billion and is part of the services sector and transportation industry. Shares are up 46.14% year-to-date as of the close of trading on Friday.

Hawaiian Holdings, Inc., through its subsidiary, Hawaiian Airlines, Inc., engages in the scheduled air transportation of passengers and cargo. The company has a P/E ratio of 14.9. Currently, there are 4 analysts who rate Hawaiian Holdings a buy, 2 analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on HA - FREE

TheStreet Quant Ratings

rates Hawaiian Holdings as a

buy

. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, expanding profit margins, good cash flow from operations and notable return on equity. We feel its strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full

Hawaiian Holdings Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Cell Therapeutics (CTIC) - FREE Research Report

Plunkett Matthew, who is EVP, Corporate Development at Cell Therapeutics, sold 10,000 shares at $1.38 on Nov. 6, 2015. Following this transaction, the EVP, Corporate Development owned 630,084 shares meaning that the stake was reduced by 1.56% with the 10,000-share transaction.

The shares most recently traded at $3.01, up $1.63, or 54.11% since the insider transaction. Historical insider transactions for Cell Therapeutics go as follows:

  • 4-Week # shares sold: 295,000
  • 12-Week # shares sold: 1.5 million
  • 24-Week # shares sold: 1.6 million

The average volume for Cell Therapeutics has been 3.7 million shares per day over the past 30 days. Cell Therapeutics has a market cap of $440.5 million and is part of the health care sector and drugs industry. Shares are up 53.93% year-to-date as of the close of trading on Tuesday.

CTI BioPharma Corp., a biopharmaceutical company, engages in the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally.

Exclusive Offer: Get the latest Stock Analysis on CTIC - FREE

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.